JP2016502551A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502551A5 JP2016502551A5 JP2015545783A JP2015545783A JP2016502551A5 JP 2016502551 A5 JP2016502551 A5 JP 2016502551A5 JP 2015545783 A JP2015545783 A JP 2015545783A JP 2015545783 A JP2015545783 A JP 2015545783A JP 2016502551 A5 JP2016502551 A5 JP 2016502551A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fragment
- repeat
- toxin
- immunogenic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 25
- 230000002163 immunogen Effects 0.000 claims 15
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 8
- 101710182223 Toxin B Proteins 0.000 claims 8
- 101710182532 Toxin a Proteins 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 241000193163 Clostridioides difficile Species 0.000 claims 5
- 229930182558 Sterol Natural products 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 150000003432 sterols Chemical class 0.000 claims 4
- 235000003702 sterols Nutrition 0.000 claims 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 3
- 229930182490 saponin Natural products 0.000 claims 3
- 150000007949 saponins Chemical class 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 229920006008 lipopolysaccharide Polymers 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1221875.6 | 2012-12-05 | ||
| GB201221875 | 2012-12-05 | ||
| PCT/EP2013/075405 WO2014086787A1 (en) | 2012-12-05 | 2013-12-03 | Immunogenic composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018020900A Division JP6626521B2 (ja) | 2012-12-05 | 2018-02-08 | 免疫原性組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016502551A JP2016502551A (ja) | 2016-01-28 |
| JP2016502551A5 true JP2016502551A5 (enExample) | 2017-01-19 |
| JP6290918B2 JP6290918B2 (ja) | 2018-03-07 |
Family
ID=49724573
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545783A Active JP6290918B2 (ja) | 2012-12-05 | 2013-12-03 | 免疫原性組成物 |
| JP2018020900A Active JP6626521B2 (ja) | 2012-12-05 | 2018-02-08 | 免疫原性組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018020900A Active JP6626521B2 (ja) | 2012-12-05 | 2018-02-08 | 免疫原性組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9694064B2 (enExample) |
| EP (2) | EP2928489B1 (enExample) |
| JP (2) | JP6290918B2 (enExample) |
| CN (2) | CN104884081A (enExample) |
| AR (1) | AR093712A1 (enExample) |
| AU (1) | AU2013354186A1 (enExample) |
| BR (1) | BR112015012841B1 (enExample) |
| CA (1) | CA2893435C (enExample) |
| CY (1) | CY1121560T1 (enExample) |
| DK (2) | DK3513806T5 (enExample) |
| ES (2) | ES2939307T3 (enExample) |
| FI (1) | FI3513806T3 (enExample) |
| HR (2) | HRP20190711T1 (enExample) |
| HU (2) | HUE061273T2 (enExample) |
| LT (2) | LT3513806T (enExample) |
| PL (2) | PL2928489T3 (enExample) |
| PT (2) | PT3513806T (enExample) |
| SG (1) | SG11201503861UA (enExample) |
| SI (2) | SI2928489T1 (enExample) |
| TR (1) | TR201905272T4 (enExample) |
| WO (1) | WO2014086787A1 (enExample) |
| ZA (1) | ZA201503927B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9486515B2 (en) * | 2005-06-27 | 2016-11-08 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| CN103957931B (zh) | 2010-09-03 | 2017-10-24 | 瓦尔内瓦奥地利有限责任公司 | 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途 |
| CN103619871B (zh) | 2011-04-22 | 2016-12-14 | 惠氏有限责任公司 | 涉及突变体难辨梭菌毒素的组合物及其方法 |
| BR122016023101B1 (pt) * | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| ES2939307T3 (es) * | 2012-12-05 | 2023-04-20 | Glaxosmithkline Biologicals Sa | Composición inmunogénica |
| WO2015197737A1 (en) * | 2014-06-25 | 2015-12-30 | Glaxosmithkline Biologicals S.A. | Clostridium difficile immunogenic composition |
| CN106659799B (zh) * | 2014-07-25 | 2020-07-17 | 碧奥辛斯有限责任公司 | 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗 |
| US10533036B2 (en) | 2015-02-19 | 2020-01-14 | Immune Biosolutions Inc | Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3433264A4 (en) | 2016-03-21 | 2019-08-28 | Children's Medical Center Corporation | COMPOSITIONS AND METHODS FOR INHIBITING WNT SIGNALING |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| WO2018170238A2 (en) * | 2017-03-15 | 2018-09-20 | Novavax, Inc. | Methods and compositions for inducing immune responses against clostridium difficile |
| CN107397956A (zh) * | 2017-08-08 | 2017-11-28 | 南开大学 | 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用 |
| WO2019143552A1 (en) | 2018-01-16 | 2019-07-25 | Children's Medical Center Corporation | Compositions and methods for inhibiting wnt signaling |
| GB201804092D0 (en) * | 2018-03-14 | 2018-04-25 | Imperial Innovations Ltd | Methods and compositions |
| US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
| JP7637988B2 (ja) * | 2019-05-21 | 2025-03-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クロストリジウム・ディフィシルのワクチン組成物 |
| WO2021255690A2 (en) * | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| WO2024127215A2 (en) * | 2022-12-13 | 2024-06-20 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
| WO2024160901A1 (en) | 2023-02-02 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| JP2851288B2 (ja) | 1987-06-05 | 1999-01-27 | アメリカ合衆国 | 癌診断および管理における自己分泌運動性因子 |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| EP0382271B1 (en) | 1989-02-04 | 1994-12-21 | Akzo Nobel N.V. | Tocols as adjuvant in vaccine |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| NZ253137A (en) | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
| EP0689454B2 (en) | 1993-03-23 | 2005-02-23 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| AU709586B2 (en) | 1994-10-24 | 1999-09-02 | Ophidian Pharmaceuticals, Inc. | Vaccine and antitoxin for treatment and prevention of C. difficile disease |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| EP2305303A3 (en) | 1997-10-20 | 2013-11-13 | Sanofi Pasteur Biologics Co. | Immunization against Clostridium difficile disease |
| JP2002542169A (ja) | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
| US6733760B1 (en) * | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
| AU2001251013A1 (en) | 2000-03-28 | 2001-10-08 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| US20090028903A1 (en) * | 2005-03-23 | 2009-01-29 | Glaxosmithkline Biologicals, S.A. | Novel use |
| GB0525321D0 (en) * | 2005-12-13 | 2006-01-18 | Glaxosmithkline Biolog Sa | Novel compositions |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| PT2086582E (pt) * | 2006-10-12 | 2013-01-25 | Glaxosmithkline Biolog Sa | Vacina compreendendo uma emulsão adjuvante óleo em água |
| GB0711858D0 (en) * | 2007-06-19 | 2007-07-25 | Glaxosmithkline Biolog Sa | Vaccine |
| AU2008299885C1 (en) | 2007-09-14 | 2015-06-25 | Sanofi Pasteur Biologics, Llc | Pharmaceutical compositions containing clostridium difficile toxoids A and B |
| MX2010011412A (es) * | 2008-04-16 | 2010-11-12 | Glaxosmithkline Biolog Sa | Vacuna. |
| CA2733425A1 (en) * | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
| CN103957931B (zh) * | 2010-09-03 | 2017-10-24 | 瓦尔内瓦奥地利有限责任公司 | 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途 |
| CN107098977A (zh) * | 2011-05-27 | 2017-08-29 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| ES2939307T3 (es) * | 2012-12-05 | 2023-04-20 | Glaxosmithkline Biologicals Sa | Composición inmunogénica |
-
2013
- 2013-12-03 ES ES19159001T patent/ES2939307T3/es active Active
- 2013-12-03 DK DK19159001.7T patent/DK3513806T5/da active
- 2013-12-03 HU HUE19159001A patent/HUE061273T2/hu unknown
- 2013-12-03 TR TR2019/05272T patent/TR201905272T4/tr unknown
- 2013-12-03 PT PT191590017T patent/PT3513806T/pt unknown
- 2013-12-03 HU HUE13801540A patent/HUE043091T2/hu unknown
- 2013-12-03 SI SI201331393T patent/SI2928489T1/sl unknown
- 2013-12-03 ES ES13801540T patent/ES2721930T3/es active Active
- 2013-12-03 PL PL13801540T patent/PL2928489T3/pl unknown
- 2013-12-03 LT LTEP19159001.7T patent/LT3513806T/lt unknown
- 2013-12-03 CN CN201380063596.3A patent/CN104884081A/zh active Pending
- 2013-12-03 HR HRP20190711TT patent/HRP20190711T1/hr unknown
- 2013-12-03 CN CN202011473000.5A patent/CN112807422A/zh active Pending
- 2013-12-03 JP JP2015545783A patent/JP6290918B2/ja active Active
- 2013-12-03 PL PL19159001.7T patent/PL3513806T3/pl unknown
- 2013-12-03 FI FIEP19159001.7T patent/FI3513806T3/fi active
- 2013-12-03 EP EP13801540.9A patent/EP2928489B1/en active Active
- 2013-12-03 AU AU2013354186A patent/AU2013354186A1/en not_active Abandoned
- 2013-12-03 DK DK13801540.9T patent/DK2928489T3/en active
- 2013-12-03 LT LTEP13801540.9T patent/LT2928489T/lt unknown
- 2013-12-03 BR BR112015012841-6A patent/BR112015012841B1/pt active IP Right Grant
- 2013-12-03 AR ARP130104466A patent/AR093712A1/es unknown
- 2013-12-03 SG SG11201503861UA patent/SG11201503861UA/en unknown
- 2013-12-03 EP EP19159001.7A patent/EP3513806B1/en active Active
- 2013-12-03 US US14/649,940 patent/US9694064B2/en active Active
- 2013-12-03 SI SI201332035T patent/SI3513806T1/sl unknown
- 2013-12-03 HR HRP20230359TT patent/HRP20230359T1/hr unknown
- 2013-12-03 CA CA2893435A patent/CA2893435C/en active Active
- 2013-12-03 PT PT13801540T patent/PT2928489T/pt unknown
- 2013-12-03 WO PCT/EP2013/075405 patent/WO2014086787A1/en not_active Ceased
-
2015
- 2015-06-01 ZA ZA2015/03927A patent/ZA201503927B/en unknown
-
2017
- 2017-05-26 US US15/606,439 patent/US10130694B2/en active Active
-
2018
- 2018-02-08 JP JP2018020900A patent/JP6626521B2/ja active Active
-
2019
- 2019-04-19 CY CY20191100436T patent/CY1121560T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016502551A5 (enExample) | ||
| HRP20190711T1 (hr) | Imunogeni pripravak | |
| Skene et al. | Saponin-adjuvanted particulate vaccines for clinical use | |
| JP2012176978A5 (enExample) | ||
| HRP20140484T1 (hr) | Cjepivni pripravci koji sadrže saponinski adjuvans | |
| HRP20191291T1 (hr) | Imunogeni pripravak | |
| JP2015214545A5 (enExample) | ||
| RU2015142996A (ru) | Пептидная вакцина для предупреждения и иммунотерапии деменции альцгеймеровского типа | |
| PE20100658A1 (es) | COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y UN ADYUVANTE QUE CONTIENE QS21, COLESTEROL Y 3D-MPL | |
| ES2673556T3 (es) | Vacunas para el VHS-2 | |
| SI2280721T1 (en) | Indoleamine 2, 3-dioxygenase based immunotherapy | |
| JP2015110588A5 (enExample) | ||
| PE20161560A1 (es) | Vacuna de pcsk9 | |
| JP2009191078A5 (enExample) | ||
| JP2014530010A5 (enExample) | ||
| JP2012102105A5 (enExample) | ||
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| JP2008539187A5 (enExample) | ||
| JP2014521605A5 (enExample) | ||
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| IL276661B2 (en) | Immunogenic preparation containing staphylococcal antigens | |
| MX2018013517A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| AR079706A1 (es) | Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso | |
| JP2014508734A5 (enExample) | ||
| JP2017508006A5 (enExample) |